Search results for "Growth factor"

showing 10 items of 1300 documents

Expression of vascular endothelial growth factor receptors in the endometrium of septate uterus.

2008

Objective To compare the messenger RNA (mRNA) expression of vascular endothelial growth factor (VEGF) receptors (KDR, Flt-1, and sflt) in the different endometrial locations of septate uterus and normal uterus. Design Prospective, observational study. Setting University teaching hospital. Patient(s) Twelve women with complete septate uterus undergoing hysteroscopic metroplasty and 12 women with normal uterus. Intervention(s) Endometrial tissue samples were obtained from the endometrium covering the septum and the endometrium lining the lateral wall of the uterus. Moreover, endometrial samples were obtained from patients with normal uterus. Main Outcome Measure(s) Differences in the mRNA exp…

SeptateAdultmedicine.medical_specialtyUterusBiologyEndometriumAndrologychemistry.chemical_compoundEndometriumInternal medicinemedicineHumansProspective StudiesRNA MessengerReceptorRegulation of gene expressionMessenger RNAVascular Endothelial Growth Factor Receptor-1urogenital systemUterusObstetrics and GynecologyVascular Endothelial Growth Factor Receptor-2Vascular endothelial growth factormedicine.anatomical_structureEndocrinologyReceptors Vascular Endothelial Growth FactorReproductive MedicinechemistryGene Expression RegulationCase-Control StudiesFemaleSeptate uterusFertility and sterility
researchProduct

Shedding of Membrane Vesicles Mediates Fibroblast Growth Factor-2 Release from Cells

2003

Fibroblast growth factor-2 (FGF-2), a polypeptide with regulatory activity on cell growth and differentiation, lacks a conventional secretory signal sequence, and its mechanism of release from cells remains unclear. We characterized the role of extracellular vesicle shedding in FGF-2 release. Viable cells released membrane vesicles in the presence of serum. However, in serum-free medium vesicle shedding was dramatically down-regulated, and the cells did not release FGF-2 activity into their conditioned medium. Addition of serum to serum-starved cells rapidly induced intracellular FGF-2 clustering under the plasma membrane and into granules that colocalized with patches of the cell membrane …

SerumFGF-2 extracellular vesiclesBiologyFibroblast growth factorBiochemistryCulture Media Serum-FreeSettore MED/13 - EndocrinologiaCell Line; Tumor; Endothelial Cells; Fibroblast Growth Factor 2; Secretory VesiclesCell LineCell membraneSettore BIO/13 - Biologia ApplicataCell Line TumorSettore BIO/10 - BiochimicamedicineHumansProtein IsoformsFibroblastMolecular BiologyTumorSecretory VesiclesVesicleCell MembraneEndothelial CellsCell BiologyExtracellular vesicleSecretory VesicleCell biologyKineticsmedicine.anatomical_structureMicroscopy FluorescenceCell cultureFibroblast Growth Factor 2IntracellularJournal of Biological Chemistry
researchProduct

PRENATAL DEVELOPMENT OF TEMPORO-MANDIBULAR JOINTS: STATE OF ART

2017

The aim of this work is to analyze the state of the art of temporo-mandibular joint (MJ) to understand the varoius stage of the development of the same during embryogenesis. Various theories have been analyzed, such as the formation of apoptotic or the important role of growth factors, or the Valencia et studies in which are analyzed to numerous articular diseases in various stage of development. By the aforementioned studies show that many factors, of a different nature, are to be involved in the prenatal developlment of this important joint.

Settore BIO/16 - Anatomia Umanatemporo-mandibular joint embriyogenesis growth factors
researchProduct

Advanced electrospun matrices based on polysaccharide derivatives for applications in regenerative medicine

2021

The complete regeneration of damaged human tissues and organs is still a significant challenge. The integrative use of biomaterials, cells and bioactive factors in all-in-one devices exploits all current knowledge of materials science, nanotechnology and stem cell biology to best mimic the complex hierarchical architecture of native tissues. The artificial microenvironment design must be properly tuned to match the physicochemical features of the target, offering adequate nanoscale patterns and biological domains for cellular interactions. Scaffolds must promote and guide the regeneration route by mimicking host signalling pathways through the controlled release and retention of drugs or gr…

Settore CHIM/09 - Farmaceutico Tecnologico Applicativodruggrowth factorwound healingsynthesideliveryPolysaccharidenanofiberperiodontitiselectrospinning
researchProduct

miRNA Signature and Dicer Requirement during Human Endometrial Stromal Decidualization In Vitro

2012

Decidualization is a morphological and biochemical transformation of endometrial stromal fibroblast into differentiated decidual cells, which is critical for embryo implantation and pregnancy establishment. The complex regulatory networks have been elucidated at both the transcriptome and the proteome levels, however very little is known about the post-transcriptional regulation of this process. miRNAs regulate multiple physiological pathways and their de-regulation is associated with human disorders including gynaecological conditions such as endometriosis and preeclampsia. In this study we profile the miRNAs expression throughout human endometrial stromal (hESCs) decidualization and analy…

Sexual ReproductionRibonuclease IIISmall interfering RNAAnatomy and PhysiologyCellular differentiationGene ExpressionBioinformaticsCell morphologyTranscriptomeEndocrinologyMolecular Cell BiologyMultidisciplinarybiologyStem CellsQDeciduaRObstetrics and GynecologyCell DifferentiationForkhead Transcription FactorsCell biologyFemale Genital Diseasesmedicine.anatomical_structureMedicineFemaleResearch ArticleAdultScienceMolecular GeneticsYoung AdultmicroRNAGeneticsDeciduamedicineReproductive EndocrinologyHumansGene RegulationBiologyEmbryonic Stem CellsHomeodomain ProteinsGene Expression ProfilingReproductive SystemComputational BiologyDecidualizationFibroblastsFemale SubfertilityInsulin-Like Growth Factor Binding Protein 1MicroRNAsHomeobox A10 ProteinsGene Expression Regulationbiology.proteinStromal CellsDevelopmental BiologyDicerPLoS ONE
researchProduct

Invariant natural killer T cells treated with rapamycin or transforming growth factor-β acquire a regulatory function and suppress T effector lymphoc…

2015

Invariant natural killer T cells treated with rapamycin or transforming growth factor-β acquire a regulatory function and suppress T effector lymphocytes

Sirolimus0301 basic medicineEffectorImmunologyNKT TGFb TregsBiologyNatural killer T cellT-Lymphocytes RegulatoryCell biologySettore MED/16 - ReumatologiaMice03 medical and health sciences030104 developmental biologyInfectious DiseasesTransforming Growth Factor betaAnimalsHumansNatural Killer T-CellsImmunology and AllergyLetter to the EditorInvariant natural killer T-cellFunction (biology)Transforming growth factorCellular & Molecular Immunology
researchProduct

Cardiovascular Damage Induced by Anti-VEGF Therapy

2018

Vascular endothelial growth factor (VEGF) plays an important role in maintaining the regular homeostasis of vascular walls. VEGF binds its receptor (VEGFR) promoting the regular survival and function of endothelial cells. Anti-VEGF and anti-VEGFR drugs inhibit the action of VEGF and VEGFR. These drugs can cause cardiovascular toxic effects such as arterial hypertension, thromboembolism, myocardial ischemia and heart failure. The monoclonal antibody bevacizumab and tyrosine kinase inhibitors (sorafenib, sunitinib, pazopanib, regorafenib, axitinib, cabozantinib, ponatinib) are the main inhibitors of VEGF, VEGFR and other tyrosine kinases. In this chapter we will illustrate the cardiovascular …

SorafenibCabozantinibSunitinibbusiness.industryAxitinibVascular endothelial growth factorPazopanibchemistry.chemical_compoundchemistryRegorafenibmedicineCancer researchbusinessTyrosine kinasemedicine.drug
researchProduct

BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer.

2013

Abstract: Introduction: Several new targeted agents with anti-angiogenic properties have been developed recently, including vandetanib, sunitinib, sorafenib, bevacizumab and others. Tumor development, progression, metastasis are strongly linked to angiogenesis. Targeted agents like bevacizumab, a monoclonal antibody which targets VEGF, have been fully developed in several solid tumors. These new agents strongly advocate that targeting angiogenesis is one of the best approaches for cancer therapy. Areas covered: Those agents that target additional pro-angiogenic intracellular signaling pathways beyond VEGF signaling have also the potential to contribute to anticancer therapies. The authors p…

SorafenibIndolesLung NeoplasmsBevacizumabSettore MED/06 - Oncologia MedicaAngiogenesis InhibitorsPharmacologyVandetanibMetastasischemistry.chemical_compoundCarcinoma Non-Small-Cell LungmedicineAnimalsHumansPharmacology (medical)Lung cancerProtein Kinase InhibitorsPharmacologyNeovascularization Pathologicbusiness.industrySunitinibPharmacology. Therapyanti-angiogenesis BIBF 1120 nintedanib non-small cell lung cancer vascular endothelial growth factorGeneral MedicineProtein-Tyrosine Kinasesmedicine.diseaseVascular endothelial growth factorchemistryCancer researchNintedanibbusinessmedicine.drugExpert opinion on investigational drugs
researchProduct

Sorafenib (SFB) treated elderly patients (E) with hepatocellular carcinoma (HCC): Chromogranine A (CGA) plus vascular endothelial growth factor (VEGF…

2012

e14676 Background: HCC accounts for approximately 90% of all primary liver cancers, and is the fifth most common cancer in the world and prognosis is so far very poor,particularly in E patients.Between all tentative of treatment till know SFB seems to be the most promising drug in patients with advanced or metastatic HCC.Aim of the study is to investigate if SFB is efficient and safe also in E HCC patients despite the comorbidities and other problems. Objectives: To investigate if CgA and VEGF work as predicting factors of Sorafenib treatment outcomes. Methods: 51 patients, mean age 68,9 (65-85) with HCC were enrolled . Serum CgA, VEGF and αFP were evaluated at baseline and after end of tr…

SorafenibOncologyCancer ResearchPathologymedicine.medical_specialtybiologybusiness.industryVEGF receptorsTreatment outcomeCancermedicine.diseaseVascular endothelial growth factorchemistry.chemical_compoundOncologychemistryGeriatric oncologyHepatocellular carcinomaInternal medicinemedicinebiology.proteinbusinessgeriatric oncologymedicine.drug
researchProduct

The role of targeted therapy for gastrointestinal tumors

2014

Abstract: Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinic…

SorafenibOncologyVascular Endothelial Growth Factor Amedicine.medical_specialtyReceptor ErbB-2Hepatocellular carcinomaSettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntineoplastic AgentsNeuroendocrine tumorsTargeted therapyTargeted therapychemistry.chemical_compoundNeuroendocrine tumorTrastuzumabInternal medicineRegorafenibmedicineHumansGastrointestinal tumorsMolecular Targeted TherapyProtein Kinase InhibitorsGastrointestinal NeoplasmsEverolimusHepatologySunitinibbusiness.industryColorectal cancer; Gastric cancer; Gastrointestinal tumors; Hepatocellular carcinoma; Neuroendocrine tumors; Targeted therapy; Hepatology; GastroenterologyGastrointestinal tumorGastroenterologyCancermedicine.diseaseColorectal cancerErbB ReceptorsReceptors Vascular Endothelial Growth FactorchemistryHuman medicineNeuroendocrine tumorsbusinessGastric cancermedicine.drug
researchProduct